Close Menu

Silence

Silence Therapeutics has named Georg Buchner as vice president of business development.
In this role, he will work with the company's chief business officer to broaden its collaborations with pharmaceutical and biotech firms.

By Doug Macron
Silence Therapeutics this week announced that it has signed a deal under which Mirna Therapeutics will evaluate two of its proprietary delivery technologies for use with Mirna's therapeutic microRNA mimics.

Silence Therapeutics this week announced that it has signed a deal under which one of its proprietary siRNA delivery technologies will be evaluated by an undisclosed “global pharmaceutical” company.

Silence Therapeutics said last week that it has received a Japanese patent covering methods for screening a therapeutic agent to treat diseases, such as cancer, related to increased Pl3-kinase pathway activity.

Silence Therapeutics has named COO Thomas Christely as its new CEO.

As part of the restructuring, Silence has lowered the headcount at its Berlin research facility to 27 from 32.

The application claims the lipid used in its Silence's AtuPlex delivery technology.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.